Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GNRHR | P30968 | 4/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461096 | 0.89 | KMT2A (0.61) | KMT2AMEN1MAPTALDH1A1CYP3A4 | |
| SCHEMBL5470943 | 0.87 | GNRHR (0.55) | KMT2AMEN1MAPTALDH1A1CYP3A4 | |
| SCHEMBL5466815 | 0.85 | KMT2A (0.55) | KMT2AGAAMEN1MAPTNR3C1 | |
| SCHEMBL5466678 | 0.85 | MAPT (0.51) | KMT2AGAAMEN1MAPTALDH1A1 | |
| SCHEMBL5471890 | 0.84 | KMT2A (0.54) | KMT2AMEN1ALDH1A1TSHRMAPK1 | |
| SCHEMBL5467352 | 0.83 | KMT2A (0.59) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL5474826 | 0.83 | KMT2A (0.53) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL5461670 | 0.82 | GNRHR (0.53) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL5468959 | 0.82 | KMT2A (0.53) | KMT2AMEN1MAPTALDH1A1TSHR | |
| SCHEMBL5470980 | 0.82 | KMT2A (0.52) | KMT2AMEN1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070170612-A1 | PROCESS FOR INTRODUCING AT LEAST ONE CHEMICAL COMPOUND INTO AN EXTRUDER, INTRODUCTION DEVICE, EXTRUDER EQUIPPED WITH SUCH A DEVICE AND PROCESSES USING SUCH AN EXTRUDER | SOLVAY (SOCIETE ANONYME) (BE) | 2007-07-26 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KMT2A 1132/4885GAA 3884/4885MEN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.